Haertmedin (pimobendan) is indicated for the management of the signs of mild, moderate, or severe (modified NYHA Class II, III, or IV) congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM). Heartmedin is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
Key Benefits
Helps dogs suffering from congestive heart disease
Shown to increase quality and length of life in dogs